Why AgomAb Therapeutics NV’s (AGMB) Stock Is Down 5.50%
As of Monday, July 13, AgomAb Therapeutics NV’s AGMB share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Commentary & Analysis
Why AgomAb Therapeutics NV’s (AGMB) Stock Is Down 6.40%
As of Wednesday, July 08, AgomAb Therapeutics NV’s AGMB share price has dipped by 6.40%, which has investors questioning if this is right time to buy.Michael Rose
Why AgomAb Therapeutics NV’s (AGMB) Stock Is Up 6.40%
As of Monday, July 06, AgomAb Therapeutics NV’s AGMB share price has surged by 6.40%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why AgomAb Therapeutics NV’s (AGMB) Stock Is Up 10.61%
As of Thursday, July 02, AgomAb Therapeutics NV’s AGMB share price has surged by 10.61%, which has investors questioning if this is right time to sell.Michael Rose
Why AgomAb Therapeutics NV’s (AGMB) Stock Is Down 5.74%
As of Wednesday, July 01, AgomAb Therapeutics NV’s AGMB share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | AGMB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $777.1 | $674.5 | 42% |
|
| Shares Out (Mil) | 0.6 | 43.5 | 3% |
|
| Institutional Ownership | 99.8% | 84.6% | 94% |
|
| Float (Mil) | 13.8 | 47.3 | 23% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 206 | 290 | 46% |
|
| Price Change (52-week) |
na | 69.3% | na |
|
| Growth | AGMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AGMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($73) | ($11) | 13% |
|
| EPS (TTM) | ($168.160) | ($0.700) | 0% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($6) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 18% |
|
| Enterprise Value (Q1) (Mil) | $926 | $536 | 40% |
|
| Valuation | AGMB | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AGMB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.1% | na |
|
| Net Margin | na | (1.4%) | na |
|
| ROA | (81.4%) | (24.1%) | 7% |
|
| ROE | 74.1% | (21.0%) | 95% |
|
| Liabilities to Assets | 14.8% | 32.3% | 9% |
|
| F-Score | 1 | 3 | na |
|
AgomAb Therapeutics NV did not pass any screens on 9/4/2026.
